St Pancras Clinical Research

What St Pancras Clinical Research does

St Pancras Clinical Research (SPCR) is a privately held, independent clinical research site management organization founded in London in 2016. It conducts Phase II and III clinical trials for pharmaceutical, biotechnology, and CRO sponsors, with therapeutic-area depth in Alzheimer's Disease and Mild Cognitive Impairment, chronic pain conditions (Complex Regional Pain Syndrome, osteoarthritis, chronic lower back pain, trigeminal neuralgia, migraines), diabetes and diabetic neuropathy, depression and neuropsychiatric conditions (PTSD, alcohol and opioid use disorders), dermatological conditions, and rare diseases. SPCR operates three clinical sites in England — London (Barbican), Chester, and Eastbourne — supported by an in-house laboratory, a sleep lab collaboration, a dedicated psychedelic testing room, and contracted relationships with The Doctors Laboratory, Alliance Medical, and INVICRO for sample processing and imaging.

SPCR's service platform spans study feasibility and planning, regulatory submission support, clinical trial management, participant recruitment, and consultancy in pain and cognition trial design. Recruitment is powered by an in-house database of 24,000-40,000 individuals across therapeutic areas and demographics, combined with multi-channel patient outreach (radio, search, social, referrals). Quality and compliance are anchored in ISO 9001:2015 accreditation (built over eight years), GCP compliance, MHRA-aligned conduct, and a UK Home Office Controlled Drugs Licence for scheduled Investigational Medicinal Product storage. The senior team includes Chief Scientific Officer Dr Stuart Ratcliffe (35+ years' experience, 200+ trials as PI/Chief/Coordinating Investigator), supported by a Global Rater team for standardized cognitive assessments.

SPCR is compensated by study sponsors (pharmaceutical, biotech, and CRO clients) for delivering clinical research services — a professional services / fee-for-study revenue model. The company is family/management-owned with no disclosed external institutional investors or funding rounds. Customer logos are not publicly named, but the offering is squarely enterprise B2B, with swift feasibility projections (within 48 hours) and experienced GMC-licensed Principal Investigators positioned as sponsor-facing differentiators. No revenue, ARR, or pricing is publicly disclosed.

Name

St Pancras Clinical Research

Legal name

St Pancras Clinical Research Ltd.

Website

https://stpancrasclinicalresearch.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

St Pancras Clinical Research is an independent UK Site Management Organisation conducting Phase II and III clinical trials for pharmaceutical, biotech, and CRO sponsors across Alzheimer's, chronic pain, diabetes, depression, and rare diseases, operating three clinics in London, Chester, and Eastbourne.

Ownership category

akta.pro rank

Product category

Clinical Research Site Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Clinical trial services
• Site management organization
• Phase II trials
• Phase III trials
• Patient recruitment

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Clinical Trial Services: SPCR conducts Phase II and III clinical trials on behalf of pharmaceutical companies, biotech firms, and CROs. Revenue is generated through service fees for study feasibility, protocol assessment, regulatory submissions, trial management, and participant recruitment. They are compensated by study sponsors (pharma/biotech/CRO clients) for delivering clinical research services.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

St Pancras Clinical Research (SPCR) operates as an independent site management organisation delivering Phase II and III clinical trials on behalf of pharmaceutical, biotech, and CRO sponsors across the UK. It runs three clinical sites in London (Barbican), Chester, and Eastbourne, offering integrated services including feasibility assessment, protocol development, regulatory submissions, participant recruitment, clinical trial management, and consulting in chronic pain, cognition, and metabolic disease.

Product overview

St Pancras Clinical Research (SPCR) is a leading independent clinical research company that operates as a site management organization delivering Phase II and III clinical trials. The company offers a unified service platform comprising study feasibility and planning, clinical trial management, participant recruitment, and clinical trial consultancy. SPCR specializes in therapeutic areas including Alzheimer's Disease and Mild Cognitive Impairment, chronic pain conditions (CRPS, osteoarthritis, lower back pain, trigeminal neuralgia, migraines), diabetes and diabetic neuropathy, depression (treatment resistant, Major Depressive Disorder), neuropsychiatric conditions (PTSD, alcohol use disorder, opioid use disorder), dermatological conditions, and rare diseases. The company operates research sites in London, Chester, and Eastbourne, providing facilities including in-house laboratory, nine consulting rooms, overnight accommodation, dedicated psychedelic testing room, and sleep lab. They partner with scanning centers (Alliance Medical, INVICRO) for imaging services and The Doctors Laboratory for sample processing, utilizing Zoho for patient data management and DocuSign for electronic signatures.

Differentiator

Problem solved

Functional benefit

Products and services

• Phase II Clinical Trials Phase II clinical trials involving several hundred participants living with the condition the medication is designed to treat, monitoring effectiveness and gathering data on reported side effects over several years.
• Phase III Clinical Trials Phase III clinical trials involving up to 3,000 participants, thoroughly evaluating how new medications work compared to current treatments, required for drug approval.
• Study Feasibility and Planning Feasibility team provides swift and accurate projections for reliable budgeting and project management, including protocol assessment, contract negotiation, and regulatory approval for fast set-up times.
• Clinical Trial Management Dedicated project teams ensure timely, high-quality research data delivery with experienced GMC licensed Principal and Sub-Investigators and in-house quality assurance.
• Participant Recruitment Proven recruitment strategies with low screen-fail rates and high retention levels, using tailored combination of traditional and cutting-edge approaches with access to diverse populations.
• Clinical Trial Consultancy World-leading academic and practical support to guide design and delivery of key development studies in pain and cognition, including Proof Of Concept study design and execution, and Protocol Development.
• Alzheimer's Disease and Mild Cognitive Impairment Clinical Trials Clinical trials for Alzheimer's Disease and Mild Cognitive Impairment (MCI), featuring Amyloid PET Imaging, lumbar punctures, cognitive assessments, and Mini Mental State Examinations.
• Chronic Pain Clinical Trials Clinical trials for chronic pain conditions including Complex Regional Pain Syndrome (CRPS), osteoarthritis, chronic lower back pain, trigeminal neuralgia, and migraines.
• Diabetes and Diabetic Neuropathy Clinical Trials Clinical trials for diabetes and diabetic neuropathy, offering opportunities for new medicines to treat pain associated with neuropathy in both diabetic neuropathy and small fibre neuropathy.
• Depression Clinical Trials Clinical trials for treatment resistant depression, Major Depressive Disorder, and remitted depression, with access to specialist facilities and in-house consultant psychiatrists.
• Neuropsychiatric Clinical Trials Clinical trials for PTSD, alcohol use disorder, opioid use disorder, and postpartum depression, working with psychotherapists, trained mentors and psychiatrists.
• Dermatological Clinical Trials Clinical trials for dermatological conditions including hidradenitis suppurativa and hay fever.
• Rare Disease Clinical Trials Clinical trials for rare diseases including IgA Nephropathy (Berger's Disease), Pachyonychia Congenita, and Gorlin Syndrome, with partnership with Gorlin Syndrome Group charity.
• Global Rater Services In-house experienced Global Rater team for performing high quality, standardised cognitive assessments.

Quantifiable outcome

• Over 60 complex clinical trials successfully delivered since 2017
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• Gorlin Syndrome GroupminorStrategic or Co-development PartnerSPCR partnered with the Gorlin Syndrome Group, a UK charity offering guidance and information to individuals with Gorlin Syndrome, their families and carers. The partnership aims to raise awareness about Gorlin Syndrome and clinical trial opportunities for those living with the condition.
• William Harvey Research InstituteminorStrategic or Co-development PartnerProfessor Arthur Tucker, Professor of Therapeutic Innovation & Adoption at William Harvey Research Institute, London, and past NRES Advisory Board Member, serves as an advisor to SPCR on REC strategy, quality, regulatory compliance, ethical issues and policy development.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• IQVIA: Global CRO with the Synexus site network. Competes with SPCR for multi-country Phase II/III trials and increasingly for single-country UK feasibility placements through its owned site network.
• Parexel International: Large global CRO with significant UK clinical operations and biopharmaceutical clients. Competes indirectly for the same UK Phase II/III placement work SPCR targets, especially for neuroscience and pain programmes.
• Quotient Sciences: UK-headquartered drug development services organisation offering clinical and manufacturing services. Broader incumbent versus SPCR's niche SMO focus, but competes for the same UK clinical trial service contracts.
• Labcorp Drug Development (formerly Covance): Global clinical development services provider with extensive UK central-laboratory and clinical operations footprint. Competes with SPCR for large pharma full-service trial contracts but does not replicate its specialist site delivery.

Others

• NIHR Clinical Research Network: UK government-funded clinical research infrastructure supporting NHS-based trial delivery. Thematically adjacent, providing patient recruitment and site coordination that competes with private SMOs for publicly funded UK trials and patient referrals.

Direct peers

• Re:Cognition Health: UK specialist clinical trial site focused on Alzheimer's Disease and other cognitive disorders. Closely mirrors SPCR's flagship therapeutic specialism and operates a comparable London-based site model.
• Panthera Clinical Research: UK-based clinical trial site network (formerly part of Synexus) running Phase II–III trials across multiple therapeutic areas. Comparable multi-site UK independent SMO with similar sponsor base.
• MAC Clinical Research: UK-based clinical research site network delivering Phase II–III trials across multiple therapeutic areas. Direct comparable to SPCR as a multi-site UK independent SMO targeting pharma and biotech sponsors.
• Hammersmith Medicines Research: London-based early-phase clinical research unit running Phase I and first-in-human trials. Comparable independent UK clinical research business with strong sponsor relationships and central London clinic footprint.
• Richmond Pharmacology: London-headquartered clinical pharmacology CRO conducting Phase I–III trials, including complex early-phase studies. Comparable as a London-based, independent UK clinical research organisation serving pharma/biotech sponsors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/stpancrasclinicalresearch
• LinkedInlinkedin.com/company/st.-pancras-clinical-research
• Instagraminstagram.com/stpancrasclinical
• TikToktiktok.com/@stpancrasclinical
• Xx.com/stpancrasclinic

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about St Pancras Clinical Research